Topic
Wuxi AppTec is Asia's largest provider of contract pharmaceutical research, helping drug makers shorten their discovery and development procedures. Its platform is used by more than 6,000 customers, including biotech and pharmaceutical companies, research institutions, researchers, scientists and entrepreneurs in more than 30 countries. The company was founded by Ge Li, who also chairs Wuxi Biologics.
Bipartisan support on show amid concern ‘every bit of value flowing’ to companies in the industry ‘will be used to strengthen the CCP and the PLA’.
In a letter dated February 12, the lawmakers told Treasury Secretary Janet Yellen, Defence Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the global pharmaceutical giant’s links to China’s Communist Party and military threatened US national security.
Chinese electric-car maker Li Auto and pharmaceutical company WuXi Apptec will join the Hang Seng Index as new constituents next month, according to the latest quarterly review by Hong Kong’s index compiler.
Insilico Medicine, a Hong Kong-based artificial intelligence (AI) biotechnology company, hopes to add momentum to the city’s health technology industry with the development of its AI-discovered drug.
Wuxi AppTec’s executives say they will fully comply with stringent US requirements as they pursue deals in life sciences and biotech.
Shares of the medical researcher, which listed in Shanghai this month after delisting from New York in 2015, have surged almost five-fold from its IPO price
Mainland’s leading biotech firm privatised in New York two years ago, but has been fast-tracked towards the A-share market just seven weeks after applying to list